Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Status: Enrolling
Updated:  12/19/2012
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma
Status: Enrolling
Updated: 12/19/2012
University of Arkansas for Medical Sciences/MIRT
mi
from
Little Rock, AR
Click here to add this to my saved trials
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated:  12/19/2012
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated: 12/19/2012
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated:  12/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
Status: Enrolling
Updated: 12/19/2012
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
Status: Enrolling
Updated:  12/19/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
Status: Enrolling
Updated: 12/19/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Status: Enrolling
Updated:  1/14/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Status: Enrolling
Updated: 1/14/2013
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  1/14/2013
Yale Cancer Center
mi
from
New Haven, CT
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 1/14/2013
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated:  1/17/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated: 1/17/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated:  1/17/2013
Pfizer Investigational Site
mi
from
Houston, TX
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated: 1/17/2013
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated:  1/17/2013
Pfizer Investigational Site
mi
from
Seattle, WA
A Study Of PF-04449913 In Select Hematologic Malignancies
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Status: Enrolling
Updated: 1/17/2013
Pfizer Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Robert H. Lurie Comprehensive Cancer Center Northwestern University
mi
from
Chicago, IL
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Robert H. Lurie Comprehensive Cancer Center Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Johns Hopkins Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated:  1/23/2013
Institute for Drug Development
mi
from
San Antonio, TX
MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status: Enrolling
Updated: 1/23/2013
Institute for Drug Development
mi
from
San Antonio, TX
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
Mount Sinai School of Medicine
mi
from
New York, NY
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
New York University Cancer Institute
mi
from
New York, NY
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
New York University Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated:  1/23/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Status: Enrolling
Updated: 1/23/2013
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  1/31/2013
Hillman Cancer Center
mi
from
Pittsburgh, PA
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 1/31/2013
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
University of Maryland Medical Center
mi
from
Baltimore, MD
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
Cornell - Weill Medical College of Cornell University
mi
from
New York, NY
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
Cornell - Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated:  2/12/2013
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Zarnestra in Newly Diagnosed Acute Myelogenous Leukemia (AML)With 2 Gene Expression Signature Ratio
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio
Status: Enrolling
Updated: 2/12/2013
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  3/1/2013
Stanford University Medical Center Stanford U
mi
from
Stanford, CA
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 3/1/2013
Stanford University Medical Center Stanford U
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  3/1/2013
Dana Farber Cancer Institute Ctr. for Hematologic Oncology
mi
from
Boston, MA
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 3/1/2013
Dana Farber Cancer Institute Ctr. for Hematologic Oncology
mi
from
Boston, MA
Click here to add this to my saved trials
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  3/1/2013
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 3/1/2013
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  3/1/2013
Medical University of South Carolina MUSC/HCC (2)
mi
from
Charleston, SC
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 3/1/2013
Medical University of South Carolina MUSC/HCC (2)
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  3/1/2013
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3
mi
from
Nashville, TN
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 3/1/2013
Vanderbilt University Medical Center, Clinical Trials Center Vanderbilt 3
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  3/1/2013
MD Anderson Cancer Center/University of Texas Dept of MD Anderson (15)
mi
from
Houston, TX
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 3/1/2013
MD Anderson Cancer Center/University of Texas Dept of MD Anderson (15)
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization
Pilot Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization
Status: Enrolling
Updated:  3/1/2013
University of Arkansas for Medical Science
mi
from
Little Rock, AR
Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization
Pilot Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization
Status: Enrolling
Updated: 3/1/2013
University of Arkansas for Medical Science
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
A Pilot Feasibility Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
Status: Enrolling
Updated:  3/7/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
A Pilot Feasibility Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
Status: Enrolling
Updated: 3/7/2013
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Phoenix Children's Hospital
mi
from
Phoenix, AZ
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
City of Hope
mi
from
Upper San Gabriel Valley, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
City of Hope
mi
from
Upper San Gabriel Valley, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Miller Children's Hospital
mi
from
Long Beach, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Children's Hospital Central California
mi
from
Madera, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Oakland Children's Hospital
mi
from
Oakland, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Oakland Children's Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
UCSF School of Medicine
mi
from
San Francisco, CA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
The Children's Hospital, University of Colorado
mi
from
Aurora, CO
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
The Children's Hospital, University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
University of Miami Cancer Center
mi
from
Miami, FL
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
University of Miami Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Childrens Memorial
mi
from
Chicago, IL
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Childrens Memorial
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated:  3/11/2013
Johns Hopkins University
mi
from
Baltimore, MD
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML
Status: Enrolling
Updated: 3/11/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials